Table 2.
Baseline clinical characteristics, and functional and exercise capacity of enrolled patients.
| Variables | Baseline characteristics |
|---|---|
| N | 42 |
| Age (yrs) | 45 ± 15 |
| Gender (female, n) | 36 |
| Duration of disease (yrs) | 4.5 ± 4.1 |
| JVD present (Y/N) | 12/30 |
| Edema (Y/N) | 23/19 |
| BSA (m2) | 1.77 ± 0.20 |
| Pulse pressure (mm Hg) | 38 ± 11 |
| Race (n) | |
| Caucasian | 24 |
| Hispanic | 10 |
| African American | 6 |
| Asian | 2 |
| Etiology (n) | |
| IPAH | 19 |
| CVD | 12 |
| CHD | 6 |
| HIV | 1 |
| Hereditary | 4 |
| WHO FC (I, II/III), n | 3/24/15 |
| Six-min walk distance, m | 437 ± 109 |
| Borg dyspnea score | 2.5 ± 1.7 |
BSA: body surface area; BUN: blood urea nitrogen; CCB: calcium channel blocker; CHD: congenital heart disease; CVD: collagen vascular disease; GFR: glomerular filtration rate; IPAH: idiopathic pulmonary arterial hypertension; JVD: jugular vein distention; PDE-5 inh: phosphodiesterase 5 inhibitor; PG: prostacyclin analog; WHO FC: World Health Organization functional classification.